Wednesday’s Biotech Stocks Trading; LGND, CTIC, AVII, DNDN, OTC: AEMD
Point Roberts, WA- September 08, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for September 07, 2011.
Aethlon Medical, Inc. (OTC:AEMD) closed lower by 3.03% to $0.0640 on volume of 164K shares and is now trading higher in the morning session, up OVER 15%. The Company recently reported it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
Top gaining stocks in the sector yesterday included Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded higher by 1.92 (13.68%) and closed at new multi-year high of $15.95. Yesterday’s rally was followed by sharp fall of 10% in the past one week. So far this year, the stock has jumped over 79%.
Cell Therapeutics, Inc. (NASDAQ:CTIC) continued to move higher and rose another 8.85% to $1.23. The stock has been showing strong support at $1 mark and has jumped about 20% in the past one month. The stock has 52-week range of $1-$3.33.
AVI BioPharma, Inc. (NASDAQ:AVII) shares also climbed 0.08 (7.41%) to $1.16 bouncing back from its recent fall of about 8% in the past one week. The stock had made its new 52-week low of $1.02 earlier during this week. The stock has 52-week range of $1.02-$2.74.
Dendreon Corporation (NASDAQ:DNDN) gained 0.80 (7.40%) to $11.61 on high volume. The company’s management will host a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET to provide a structural and business update on the company.
Biotech Medical Company Snapshot for Aethlon Medical (OTCBB: AEMD)
Visit the AEMD showcase page on Investorideas.com
The Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
James A. Joyce
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com